DePuy Spine, Inc.
Genetics Influence ProgrssionEmpowering Informed DecisionsConfidence in Patient Care
ScoliScore AIS Prognostic Test
Current Prognostic Standards
Familial Characteristics of AIS
Resources
Genetics Influence Progression

Girls

Genetics Influence Progression

The existing methods of assessing curve progression are based on reported observational criteria alone, and may result in inefficient patient care. Recent studies51 have shown a strong genetic link to AIS progression and have paved the way for science based, personalized patient care decisions.
 
Axial BiotechDePuy SpineSmith & NephewThis site is published by DePuy Spine, Inc. which is solely responsible for its contents. It is intended for visitors from the U.S.

The SCOLISCORE AIS Prognostic Test was designed and validated by Axial Biotech, Inc.
and is co-marketed and sold by both DePuy Spine, Inc. and Smith & Nephew, Inc.

Terms of Use | Legal Notice | Privacy Policy | Sitemap | Axial Biotech | Contact Axial Biotech Customer Service
Safe Harbor Policy | California Health Care Compliance Information | J&J Ethical Code for R&D
© DePuy Spine, Inc. 2012
Register  Login     Friday, May 18, 2012
Indications for Use:
The SCOLISCORE™ AIS Prognostic Test is intended for in vitro use only. The SCOLISCORE Test is indicated for Caucasian, adolescent males and females between the ages of 9-13 years with a mild curve (Cobb angle 10-25°). This test utilizes DNA extracted from a saliva specimen in a polymerase chain reaction to detect the genotypes for genetic markers found in clinical trials to be associated with severe curve progression in patients diagnosed with Adolescent Idiopathic Scoliosis (AIS). Results from the SCOLISCORE Test are intended for use as an adjunct to existing clinical and radiologic information to determine the risk of curve progression. For additional information regarding indications for use, please see the SCOLISCORE Test package insert.

Caution:
The SCOLISCORE™ Test is designed to accurately predict the likelihood of severe curve progression for patients diagnosed with Mild AIS and who received a SCOLISCORE in the Low Risk Classification (1- 50). Therefore, care should be exercised when utilizing the risk of progression for patients in the Intermediate Risk (51 � 179) and High Risk Classifications (180 � 200). The SCOLISCORE Test information should always be interpreted with all other clinical factors when determining the appropriate clinical treatment and care of patients. Under Federal law, this test may only be performed on the order of a physician and its results may only reported to the ordering physician.

DEPUY SPINE™, the DePuy Spine logo and SCOLISCORE™ are trademarks of DePuy Spine, Inc.